home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 09/04/19

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

FLORHAM PARK, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a late-breaker poster presenta...
CLRB - Cellectar Appoints Dov Elefant as Chief Financial Officer

FLORHAM PARK, N.J., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Mr. Dov Elef...

CLRB - CLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study

FLORHAM PARK, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has successfully completed...

CLRB - Cellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

FLORHAM PARK, N.J., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the second qua...
CLRB - Two shops soften view on Pfizer in premarket analyst action

Cellectar Biosciences (NASDAQ: CLRB ) initiated with Buy rating and $6 (180% upside) price target at Brookline Capital. Shares up  8%  premarket. More news on: Cellectar Biosciences, Inc., Heat Biologics, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th...

CLRB - M&A dominate premarket gainers

Acacia Communications (NASDAQ: ACIA ) +37%  on being acquired by Cisco. More news on: Acacia Communications, Inc., Camber Energy, Inc., Check-Cap Ltd., Stocks on the move, Read more ...

CLRB - Cellectar's CRL 131 Fast Track'd for DLBCL; shares up 6% premarket

The FDA designates Cellectar Biosciences' (NASDAQ: CLRB ) lead candidate CLR 131 for Fast Track review for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ... ...
CLRB - Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma

FLORHAM PARK, N.J., July 09, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administ...

CLRB - Cellectar -5.1% on 6.02M-share holder filing

Cellectar Biosciences (NASDAQ: CLRB ) is 5.1% lower postmarket after a shareholder filing to offer up to 6.02M common shares. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...

CLRB - NetworkNewsBreaks - Cellectar Biosciences, Inc. (NASDAQ: CLRB) Secures $10M Through RDO Sale, Private Placement

Clinical stage biopharmaceutical company Cellectar Biosciences (NASDAQ: CLRB) has closed a registered direct offering sale of 1,982,000 common shares and concurrent private placement of 2,018,000 common shares with institutional investors. In conjunction with the offerings, the company issued ...
Previous 10 Next 10